The combination of trastuzumab deruxtecan (Enhertu) with pertuzumab (Perjeta) as a first-line therapy for HER2-sure evolved metastatic breast cancer has been shown to diminish the possibility for disease progression or death by bigger than the most original identical outdated-of-care therapy. Sara Tolaney, MD, MPH Sara Tolaney, MD, MPH…
Learn Extra
2025-06-09
